JUN 2 1 2010 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ADENI	
In re application of: Kocsis et al.	Confirmation No.: 5014
Application No.: 10/584,661	Art Unit: 1628
Filed: September 19, 2006	Examiner: Kim, Jennifer M.
For: Novel Pharmaceutical Compositions With Increased Activity	Atty. Docket: 0103-0004

Amendment and Response to Office Action

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed on March 17, 2010, in connection with the above-identified application, the applicants provide the following amendments and remarks.

It is not believed that extensions of time or other fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 50-3626.

Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

1. (Original) A pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor.